Rapport Therapeutics, Inc. Common Stock
NASDAQ: RAPP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Abraham N. Ceesay
- Employees
- 69
- Headquarters
- Boston, United States
- IPO year
- 2024
- Market cap
- $1.5B
- Website
- https://www.rapportrx.com
Loading RAPP…
Loading profile data…Frequently asked questions about RAPP
What does Rapport Therapeutics, Inc. Common Stock (RAPP) do?
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to...
Where does RAPP trade?
Rapport Therapeutics, Inc. Common Stock (RAPP) trades on the NASDAQ Global Market.
What sector is RAPP in?
Rapport Therapeutics, Inc. Common Stock (RAPP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Rapport Therapeutics, Inc. Common Stock?
Abraham N. Ceesay is the chief executive officer of Rapport Therapeutics, Inc. Common Stock (RAPP).
Where is Rapport Therapeutics, Inc. Common Stock headquartered?
Rapport Therapeutics, Inc. Common Stock is headquartered in United States.
Does RAPP pay a dividend?
Rapport Therapeutics, Inc. Common Stock (RAPP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RAPP go public?
Rapport Therapeutics, Inc. Common Stock (RAPP) completed its initial public offering in 2024.